Ruxolitinib and Decitabine for High Risk Hematological Malignancies

NCT04582604 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Peripheral Blood Stem Cell Transplantation

Interventions

DRUG: modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine

Sponsor

Chinese PLA General Hospital